Pre-Made Lenercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F for drug discovery and mechanism of action (MOA) research

Pre-Made Lenercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tumor necrosis factor alpha (TNF-α) is a cytokine that has pleiotropic effects on various cell types. It has been identified as a major regulator of inflammatory responses and is known to be involved in the pathogenesis of some inflammatory and autoimmune diseases. Lenercept is a fusion protein combining the human p55 kDa TNF receptor and human IgG1 heavy chain, produced significant pain relief, reduction in swollen and tender joint counts, and improvement in physician- and patient-assessed disease activity scores.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-887-1mg	1mg	3090
GMP-Bios-INN-887-10mg	10mg	Inquiry
GMP-Bios-INN-887-100mg	100mg	Inquiry
GMP-Bios-INN-887-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lenercept Biosimilar, Fusion Protein targeting TNF fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting DIF/TNFSF2/TNLG1F
INN Name	Lenercept
Target	TNF
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - [TNFRSF1A (tumor necrosis factor receptor (TNFR) superfamilly member 1A, TNFAR, TNF-RI, TNF-R-I, p55, CD120a)]2 - IGHG1 Fc (Fragment constant)
VD LC	Fusion - [TNFRSF1A (tumor necrosis factor receptor (TNFR) superfamilly member 1A, TNFAR, TNF-RI, TNF-R-I, p55, CD120a)]2 - IGHG1 Fc (Fragment constant)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Roche, F. Hoffmann-La Roche Ltd. (Basel Switzerland) / Genentech Inc. (S. San Francisco CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0